CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Expert Involvement in Scientific Advice

The CADTH Scientific Advice Program includes expert input as part of the process for developing Scientific Advice. One or two clinical experts and one health economics expert (if relevant) will be engaged for each Scientific Advice application. Consideration may be given to engaging a past member of the CADTH Canadian Drug Expert Committee (CDEC) or the CADTH pan-Canadian Oncology Drug Review Expert Review Committee (pERC) as one of the experts, if possible. Experts will be selected based on their expertise in particular therapeutic or economic areas relevant to the application, and, in some cases, their past experience in considering drugs for reimbursement through CADTH committees such as CDEC or pERC. Alternate or additional experts in methodological areas relevant to the application may be consulted or considered for full participation, as required.

Experts engaged in the CADTH Scientific Advice Program participate in preparing the advice with CADTH staff, attend and participate in the face-to-face Scientific Advice meeting, and contribute to the preparation of the written CADTH Record of Scientific Advice.

External experts involved in the CADTH Scientific Advice Program are required to sign a Non-Disclosure Agreement and to comply with the Confidentiality Guidelines for CADTH Scientific Advice and the CADTH Conflict of Interest Guidelines for Contractors.

Read more about confidentiality or conflicts of interest for the Scientific Advice Program.